Autosomal Dominant Polycystic Kidney Disease Adpkd clinical trials

Explore recruiting autosomal dominant polycystic kidney disease adpkd clinical trials.

Recruiting autosomal dominant polycystic kidney disease adpkd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Autosomal Dominant Polycystic Kidney Disease Adpkd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Spain, Portugal, Germany, Netherlands, France, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi- centre, 2 parallel arms randomized controlled trial

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT)

Spain, France, Netherlands, Belgium, Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease

Netherlands, Austria, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants

France, Germany, Italy, Belgium, Spain, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Autosomal Dominant Polycystic Kidney Disease Adpkd trials by city

Autosomal Dominant Polycystic Kidney Disease Adpkd in Toronto Autosomal Dominant Polycystic Kidney Disease Adpkd in Vancouver Autosomal Dominant Polycystic Kidney Disease Adpkd in Montreal Autosomal Dominant Polycystic Kidney Disease Adpkd in Calgary Autosomal Dominant Polycystic Kidney Disease Adpkd in Edmonton Autosomal Dominant Polycystic Kidney Disease Adpkd in Ottawa Autosomal Dominant Polycystic Kidney Disease Adpkd in Winnipeg Autosomal Dominant Polycystic Kidney Disease Adpkd in Quebec City Autosomal Dominant Polycystic Kidney Disease Adpkd in Hamilton Autosomal Dominant Polycystic Kidney Disease Adpkd in Kitchener Autosomal Dominant Polycystic Kidney Disease Adpkd in London Autosomal Dominant Polycystic Kidney Disease Adpkd in Halifax Autosomal Dominant Polycystic Kidney Disease Adpkd in New York Autosomal Dominant Polycystic Kidney Disease Adpkd in Los Angeles Autosomal Dominant Polycystic Kidney Disease Adpkd in Chicago Autosomal Dominant Polycystic Kidney Disease Adpkd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease